Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)

SAN CARLOS, Calif., May 30 Nektar Therapeutics(Nasdaq: NKTR) will host a meeting and Webcast on Monday, June 2, 2008 at6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102(PEG-irinotecan). The Webcast will include a presentation by featured speakerDr. Daniel D. Von Hoff, M.D., F.A.C.P, the lead investigator for the NKTR-102Phase 1 trial. Dr. Von Hoff is Physician-in-Chief and Senior Investigator atthe Translational Genomics Research Institute (TGen), Chief Scientific Officerfor the Scottsdale Clinical Research Institute at Scottsdale Healthcare, andChief Scientific Officer of US Oncology.

A live audio-only Webcast of this presentation can be accessed beginningat 6:30 PM Central Time on June 2, 2008 through a link posted on the Nektarwebsite: http://www.nektar.com/wt/page/asco. A replay will also be accessiblethrough the same link through June 15, 2008.

To attend this event in person, please RSVP no later than Sunday, June 1,2008 to Vanessa Rivas: [email protected].

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops andenables differentiated therapeutics with its industry-leading PEGylation andpulmonary drug development platforms. Nektar PEGylation technology hasenabled eight approved products for partners, which include leadingpharmaceutical and biotechnology companies. Nektar also develops its ownproducts by applying its PEGylation and pulmonary technology platforms toexisting medicines with the objective to enhance performance, such asimproving efficacy, safety and compliance.

Contact: Jennifer Ruddock, +1-650-283-6253, [email protected]: 6:00 - 6:30 PM (Central Time) -- Registration 6:30 PM (Central Time) -- Webcast presentation Location: Fulton's on the River Riverfront Room and Veranda 315 N. LaSalle Street Chicago, IL 60610

SOURCE Nektar Therapeutics

Latest Press Release on General News

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...

A 2017 Hyundai Elantra and 760,000 kilometres of life-saving blood donation deliveries

Mr. Tim German's 2017 Hyundai Elantra a.k.a. "Dark Angel," was bought new from Steele Hyundai Halifax and now has more than 760,000 kilometres on the odometer. With his Elantra, Mr....

Philips Respironics Reaches Agreement with US Government on a Consent Decree Creating a Clear Path Forward

April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA ...